Fig. 1 · Structure

Documents & Downloads

Olanzapine (LY170053)

Cat. No. A10667 CAS 132539-06-1

5-HT Receptors/D2 dopamine receptor antagonist

Olanzapine(Zyprexa) is a high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
5-HT2
D2 receptor

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 0.1 μM Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method [PMID: 26227779]
WI-38 EC50 > 100 μM Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay [PMID: 17893158]
WI-38 CC50 > 100 μM Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay [PMID: 17893158]

Olanzapine (LY170053) Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Olanzapine (LY170053) from 2 published references. In vitro models include Escherichia coli NC101. In vivo models include C57BL/6J females.

Olanzapine (LY170053) In Vitro Studies

Olanzapine at 537 µg/ml completely inhibited growth of Escherichia coli NC101 in a design including IsoVitalex 1%. The comparison used rich medium plus DMSO vehicle only. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Growth Inhibition in Escherichia coli

Cell-based study · Escherichia coli NC101 [1]

Escherichia coli NC101 was exposed to Olanzapine at 537 µg/ml in a design including IsoVitalex 1%. Growth was completely inhibited compared with rich medium plus DMSO vehicle only.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
optical density at 600 nm wavelengthgrowth inhibition completely inhibited by 537 µg/ml olanzapine[1]

Literature-Reported Treatment Conditions

Treatment concentration
537 µg/ml
Exposure duration
monitored every 15 min
Method
in a 96 well plate
Vehicle
DMSO
Co-treatment
Other interventions in this design: IsoVitalex 1%. Compound effect isolated by the comparison: rich medium (brain heart infusion, BHI) plus vehicle (dimethylsulfoxide) only.
Methods and source locations

Compound reported in the paper: Olanzapine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Bacterial growth-inhibition assays (S30, S32, S33, S34); Results > Olanzapine has direct and specific antimicrobial action in vitro (S91, S94); Figure 5 legend (S122, S123)

optical density at 600 nm wavelength: optical density at 600 nm wavelength; comparator: rich medium (brain heart infusion, BHI) plus vehicle (dimethylsulfoxide) only — Results > Olanzapine has direct and specific antimicrobial action in vitro (S94); Figure 5 legend (S122)

Olanzapine (LY170053) In Vivo Studies

Under conventional conditions, C57BL/6J females receiving Olanzapine at 50 mg/kg of diet gained 4.6 grams more than untreated mice receiving the same high fat diet during the first 7 weeks of treatment. In adult male Sprague-Dawley rats trained to discriminate clozapine from vehicle, Olanzapine at 1.0 mg/kg i.p. produced full substitution for clozapine. In adult male and female B6129 inbred mice trained in clozapine discrimination, Olanzapine at 0.5 mg/kg s.c. also produced full substitution in the vehicle-controlled comparison. [1,2]

Weight gain under conventional conditions

Animal study · C57BL/6J females [1]

Olanzapine was compounded into high fat (45 kcal%) food at a concentration of 50 mg/kg of diet. Under conventional conditions in the strain survey, olanzapine-treated C57BL/6J females had gained 4.6 grams more than untreated mice during the first 7 weeks of treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
weight gainReported result Under conventional conditions in the strain survey, olanzapine-treated C57BL/6J females had gained 4.6 grams more than untreated mice (95% CI for difference 1.67–7.48 grams; p = 8.81×10−3) during the first 7 weeks of treatment.[1]

Conditions shared by the study groups

Route
compounded into feed
Treatment course
the first 7 weeks of treatment
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Olanzapine 50 mg/kg of dietthe same high fat diet (D09092903), minus olanzapineUnder conventional conditions in the strain survey, olanzapine-treated C57BL/6J females had gained 4.6 grams more than untreated mice (95% CI for difference 1.67–7.48 grams; p = 8.81×10−3) during the first 7 weeks of treatment.[1]
Olanzapine 50 mg/kg of diet
Model: C57BL/6J females
Reported limits: Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: Olanzapine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Olanzapine administration (S1, S4); Results > Olanzapine potentiates weight gain on high-fat diet (S55, S56); Results > Gut microbiota is necessary and sufficient for olanzapine-induced weight gain (S64)

weight gain: weight gain; comparator: the same high fat diet (D09092903), minus olanzapine — Results > Olanzapine potentiates weight gain on high-fat diet (S56); Results > Gut microbiota is necessary and sufficient for olanzapine-induced weight gain (S64)

Olanzapine 50 mg/kg of diet · Materials and Methods > Olanzapine administration (S1); Results > Olanzapine potentiates weight gain on high-fat diet (S55); Results > Gut microbiota is necessary and sufficient for olanzapine-induced weight gain (S64)

Clozapine Discrimination in Male Rats

Animal study · Ten adult male Sprague-Dawley rats; trained to discriminate 1.25 mg/kg clozapine from its vehicle [2]

Adult male Sprague-Dawley rats trained to discriminate clozapine from vehicle received Olanzapine at 1.0 mg/kg i.p., 30 min prior to session onset. Compared with vehicle, Olanzapine yielded full substitution for clozapine, with 84.91 (5.46) % CLZ-lever resp. (±SEM).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
% CLZ-lever resp. (±SEM); Substitution for CLZReported result 84.91 (5.46) % CLZ-lever resp. (±SEM); Full[2]

Conditions shared by the study groups

Route
i.p.
Treatment course
30 min prior to session onset
Vehicle
distilled water with 2–3 drops of lactic acid and pH-adjusted to 6.0–7.0 with NaOH
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Olanzapine 1.0 mg/kgvehicle84.91 (5.46) % CLZ-lever resp. (±SEM); Full[2]
Olanzapine 1.0 mg/kg
Model: Ten adult male Sprague-Dawley rats; trained to discriminate 1.25 mg/kg clozapine from its vehicle
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: Olanzapine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Subjects (S56); Materials and Methods > Drug discrimination procedure (S69, S74); Materials and Methods > Drugs (S96, S100, S101); Table 1 (T1.h1, T1.r4)

% CLZ-lever resp. (±SEM); Substitution for CLZ: % CLZ-lever resp. (±SEM); Substitution for CLZ; comparator: vehicle — Table 1 (T1.h1, T1.r4)

Olanzapine 1.0 mg/kg · Materials and Methods > Drug discrimination procedure (S74); Materials and Methods > Drugs (S100, S101); Table 1 (T1.h1, T1.r4)

Clozapine Discrimination in Inbred Mice

Animal study · Ten adult B6129 inbred mice (male, n = 7; female, n = 3); trained to discriminate 1.25 mg/kg clozapine from its vehicle [2]

Adult male and female B6129 inbred mice trained to discriminate clozapine from vehicle received Olanzapine at 0.5 mg/kg s.c., 30 min prior to session onset. Compared with vehicle, Olanzapine yielded full substitution for clozapine, with 87.75 (6.19) % CLZ-lever resp. (±SEM).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
% CLZ-lever resp. (±SEM); Substitution for CLZReported result 87.75 (6.19) % CLZ-lever resp. (±SEM); Full[2]

Conditions shared by the study groups

Route
s.c.
Treatment course
30 min prior to session onset
Vehicle
distilled water with 2–3 drops of lactic acid and pH-adjusted to 6.0–7.0 with NaOH
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Olanzapine 0.5 mg/kgvehicle87.75 (6.19) % CLZ-lever resp. (±SEM); Full[2]
Olanzapine 0.5 mg/kg
Model: Ten adult B6129 inbred mice (male, n = 7; female, n = 3); trained to discriminate 1.25 mg/kg clozapine from its vehicle
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: Olanzapine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Subjects (S62); Materials and Methods > Drug discrimination procedure (S69, S75); Materials and Methods > Drugs (S96, S99); Table 1 (T1.h1, T1.r11)

% CLZ-lever resp. (±SEM); Substitution for CLZ: % CLZ-lever resp. (±SEM); Substitution for CLZ; comparator: vehicle — Table 1 (T1.h1, T1.r11)

Olanzapine 0.5 mg/kg · Materials and Methods > Drug discrimination procedure (S75); Materials and Methods > Drugs (S99); Table 1 (T1.h1, T1.r11)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 132539-06-1
Applications 5-HT Receptors/D2 dopamine receptor antagonist
Formula C17H20N4S
Molecular Weight 312.44
Synonyms Zyprexa; Zalasta; Zolafren; Olzapin; Oferta; Zypadhera; LY170053
SMILES
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 55 mg/mL (176.03 mM)
Water Insoluble
Ethanol 8 mg/mL (25.6 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Olanzapine (LY170053) Research References

  1. [1] Morgan AP, Crowley JJ, Nonneman RJ, et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS One (2014). PMID: 25506936 DOI: 10.1371/journal.pone.0115225 Source material
  2. [2] Manvich DF, Webster KA, Foster SL, et al. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Sci Rep (2018). PMID: 29497149 DOI: 10.1038/s41598-018-22116-z Source material

Added to your cart

View Cart Checkout
Loading...